(AOF) – In 2021, OSE Immunotherapeutics posted a net loss of 16.85 million euros compared to a loss of 16.555 million in 2020. The biotech’s current operating loss stood at 16.625 million, compared to 18.989 million a year earlier. early. Revenue reached €26 million, mainly related to licensing agreements and milestone payments. In 2020, it had reached 10.432 million. The main expenses are on R&D and account for 75% of total expenses, the company said.
As of December 31, 2021, the cash position was €33.6 million compared to €29.4 million as of December 31, 2020. Considering its current clinical development and R&D programs, OSE Immunotherapeutics estimates that its cash should allow it to finance its activities until the first quarter of 2023 without integrating other income from new license agreements and research tax credits.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.